Just published: “Suprachoroidal delivery of axitinib, combined with pan-VEGF in…
[ad_1]
Just published: https://t.co/WYQcf8TY9n “Suprachoroidal delivery of axitinib, combined with pan-VEGF inhibition activity of axitinib, has the potential to provide additional benefits compared to the current standard of care with intravitreal anti–VEGF-A agents.”
#retina #AMD
[ad_2]
Source by Thomas Ciulla, MD, MBA